Intracranial Hypertension Induced by Megestrol Acetate Withdrawal

Update Item Information
Title Intracranial Hypertension Induced by Megestrol Acetate Withdrawal
Creator Laraib Z. Safeer; Madhuri Chilakapati; Veeral S. Shah
Affiliation Department of Ophthalmology (LZS, MC, VSS), Baylor College of Medicine, Texas Children's Hospital, Houston, Texas
Abstract Intracranial hypertension has been associated with endocrine dysregulation in conditions such as obesity, pregnancy, oral contraceptive use, excess of Vitamin A, Addison disease, and corticosteroid use/withdrawal (1-6). Megestrol acetate (MA), commercially known as Megace, is a synthetic progesterone used as an appetite stimulant for cachexia secondary to cancer or AIDS and more recently used to treat failure to thrive (FTT) in the pediatric population (7-10). MA administration has been linked to adrenal insufficiency with variable clinical presentations (10-13). The use of MA in our patient links MA usage with intracranial hypertension.
Subject Appetite Stimulants / pharmacology; Child; Failure to Thrive / drug therapy; Humans; Intracranial Hypertension / diagnosis; Intracranial Hypertension / etiology; Intracranial Hypertension / physiopathology; Intracranial Pressure / physiology; Male; Megestrol Acetate / pharmacology; Optic Disk / pathology; Tomography, Optical Coherence; Withholding Treatment
OCR Text Show
Date 2019-03
Language eng
Format application/pdf
Type Text
Publication Type Journal Article
Source Journal of Neuro-Ophthalmology, March 2019, Volume 39, Issue 1
Collection Neuro-Ophthalmology Virtual Education Library: Journal of Neuro-Ophthalmology Archives: https://novel.utah.edu/jno/
Publisher Lippincott, Williams & Wilkins
Holding Institution Spencer S. Eccles Health Sciences Library, University of Utah
Rights Management © North American Neuro-Ophthalmology Society
ARK ark:/87278/s6gr2n8n
Setname ehsl_novel_jno
ID 1595785
Reference URL https://collections.lib.utah.edu/ark:/87278/s6gr2n8n
Back to Search Results